Cargando…

Health outcomes, education, healthcare delivery and quality – 3038: The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients

Detalles Bibliográficos
Autores principales:	Yalcin, Arzu Didem, Bisgin, Atil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2013
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643273/ http://dx.doi.org/10.1186/1939-4551-6-S1-P212

Ejemplares similares

Health outcomes, education, healthcare delivery and quality – 3052. IL-17, IL-18, TGF-beta and GMCSF levels in patients with allergic asthma: Its relation to omalizumab treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Mechanisims of asthma and allergic disease - 1088. Increased serum strail level in newly diagnosed stave-iv lung adenocarcinoma but not sqamous cell carcinoma, is correlated with age and smoking
por: Kargi, Aysegul, et al.
Publicado: (2013)

Basic and clinical immunology – 3031. The correlation between serum protemics patterns of sTRAIL and CXCL8 with FDG-PET/CT findings in bevacizumab treated colon cancers
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Mechanisims of asthma and allergic disease – 1066. Ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Environmental and occupational respiratory diseases – 1062. The climate and aero allergens in Mediterranean region and allergen sensitivity in allergic rhinoconjuctivitis and allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer
por: Bisgin, Atil, et al.
Publicado: (2012)

Immunotherapy – 2071. Strail levels decreased after allergen-subcutaneous specific immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Environmental and occupational respiratory diseases – 1039. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

278 Total Antioxidant Capacity, Hydrogen Peroxide, Malondialdehyde and Total Nitric Oxide Concentrations in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Allergic diseases of the skin and drug allergies – 2027. Successful treatment with intravenous immunoglobulin and prednisolone pulse therapy of toxic epidemal necrolysis and Stevens-Johnson Syndrome
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

233 The Evaluation of Allergen Sensitivity in Allergic Rhinoconjunctivitis and Allergic Asthma Patients in Antalya, Turkey
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Pollen aero allergens and the climate in mediterranean region and allergen sensitivity in allergic rhinoconjunctivitis and allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers
por: Arık, Hasan Onur, et al.
Publicado: (2013)

IL-8, IL-10, TGF-β, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment
por: Yalcin, Arzu D., et al.
Publicado: (2012)

Omalizumab in symptomatic therapy of laryngeal oedema and urticaria attacts in a patient with post operative pulmonary carsinoid tumor
por: Yalcin, Arzu Didem, et al.
Publicado: (2015)

Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 – markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2015)

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
por: Bagnasco, Diego, et al.
Publicado: (2022)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Country-based report: the safety of omalizumab treatment in pregnant patients with asthma
por: GEMİCİOĞLU, Bilun, et al.
Publicado: (2021)

Follow-up of asthma control and quality of life after discontinuation of omalizumab in severe asthmatic patients
por: Nayci, Sibel, et al.
Publicado: (2015)

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
por: Huang, Ying, et al.
Publicado: (2017)

The effects of climate and aero allergens changes in allergic rhinoconjunctivitis and allergic asthma patients in mediterranean region between 2011 and 2012
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Vitamin D serum levels in allergic rhinitis
por: Kose, Sukran, et al.
Publicado: (2015)

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
por: Jung, Jae-Woo, et al.
Publicado: (2021)

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma
por: Jung, Jae-Woo, et al.
Publicado: (2021)

Health outcomes, education, healthcare delivery and quality – 3040. Occurrence and effects of nasal polyps in patients with bronchial asthma and/or allergic rhinitis
por: Behera, Swati
Publicado: (2013)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

3038 Examining the association between inpatient opioid prescribing and patient satisfaction.
por: Mazurenko, Olena, et al.
Publicado: (2019)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
por: Bremer, Edwin, et al.
Publicado: (2008)

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects
por: Yu, R, et al.
Publicado: (2013)

Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers
por: Celik, Betül, et al.
Publicado: (2013)

384 Jessner-kanoff Lymphocytic Infiltrate as a Side Effect of Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
por: O’Quinn, John, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k7gvsgfec8kcc7lr0odrrhduq0